Expression of p53 and Ki-67 proteins in patients with increasing severity and duration of pterygium.
Immunohistochemistry
Ki-67
P53
paraffin embedding
pterygium
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
28
5
2021
Statut:
ppublish
Résumé
Pterygium is a triangular fibrovascular subepithelial ingrowth of degenerative bulbar conjunctival tissue over the cornea. It is now considered to be a result of uncontrolled cellular proliferation as overexpression of p53 protein and Ki-67 nuclear protein was found in the epithelium. This study was done to find the expression of p53 and Ki-67 with the severity and duration of the pterygium to explain the etiopathogenesis. Data were analyzed from 43 Indian participants of all age groups. All patients were divided according to the severity of pterygium (mild, moderate, and severe groups) and according to the duration of pterygium (<4 years and >4 years). The samples were studied by immunohistochemistry by using antibodies against p53 and Ki-67 proteins considering >5% expression as significant. Of 43 cases, p53 and Ki-67 expression were positive in 33 cases. In mild, moderate, and severe cases p53 positivity was 33.3%, 78.4%, 100%, respectively. P53 expression increased with duration, 79.3% positive in <4 years, and 92.9% positive in >4 years. With increasing severity of pterygium, mild, moderate, and severe cases, Ki-67 positivity was 66.7%, 78.37%, 66.7%, respectively. Ki-67 expression with duration, 79.3% positive in <4 years, and 85.7% positive in >4 years of the duration of pterygium with no statistical significance. Our study revealed that with increasing duration and severity of pterygium, p53 expression was observed to be increasing. Ki-67 expression increased with the duration of pterygium but not with the severity.
Identifiants
pubmed: 33727444
pii: IndianJOphthalmol_2021_69_4_847_311208
doi: 10.4103/ijo.IJO_1034_20
pmc: PMC8012974
doi:
Substances chimiques
Ki-67 Antigen
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
847-850Commentaires et corrections
Type : CommentIn
Type : CommentIn
Déclaration de conflit d'intérêts
None
Références
Acta Ophthalmol Scand. 2000 Apr;78(2):216-20
pubmed: 10794261
Br J Ophthalmol. 2000 Mar;84(3):289-92
pubmed: 10684840
Korean J Ophthalmol. 2011 Dec;25(6):421-33
pubmed: 22131780
Am J Ophthalmol. 1997 Mar;123(3):404-5
pubmed: 9063255
Mol Vis. 2011;17:1687-93
pubmed: 21738398
Ophthalmology. 2000 Aug;107(8):1568-71
pubmed: 10919910
Ophthalmology. 1992 Jul;99(7):1056-61
pubmed: 1495784
Eur J Ophthalmol. 1998 Jul-Sep;8(3):157-61
pubmed: 9793769
Proc Natl Acad Sci U S A. 1986 Jan;83(1):130-4
pubmed: 3001719
Ophthalmology. 2001 May;108(5):985-8
pubmed: 11320032
Int J Mol Med. 2007 Nov;20(5):699-702
pubmed: 17912463
Clin Exp Ophthalmol. 2007 Dec;35(9):828-33
pubmed: 18173411
Br J Ophthalmol. 1995 Apr;79(4):304-5
pubmed: 7742271
Am J Pathol. 2011 Feb;178(2):817-27
pubmed: 21281814
Curr Eye Res. 1997 Dec;16(12):1179-92
pubmed: 9426949
Arch Ophthalmol. 1989 Oct;107(10):1481-4
pubmed: 2803097
Cancer Res. 1994 Sep 15;54(18):4855-78
pubmed: 8069852
Br J Ophthalmol. 1984 May;68(5):343-6
pubmed: 6712914
Br J Ophthalmol. 2000 Feb;84(2):212-6
pubmed: 10655200
Acta Histochem. 2001 Apr;103(2):159-65
pubmed: 11368097
Acta Ophthalmol Scand. 2004 Feb;82(1):64-7
pubmed: 14982048
Eye (Lond). 2002 Sep;16(5):619-21
pubmed: 12194078
Stem Cells. 2006 Jan;24(1):86-94
pubmed: 16150918
Aust N Z J Ophthalmol. 1998 May;26 Suppl 1:S2-5
pubmed: 9685008